key: cord-0715375-7xvqum64
authors: Diaz‐Arocutipa, Carlos; Saucedo‐Chinchay, Jose; Argulian, Edgar
title: Association between right ventricular dysfunction and mortality in COVID‐19 patients: A systematic review and meta‐analysis
date: 2021-09-16
journal: Clin Cardiol
DOI: 10.1002/clc.23719
sha: bf15c3f87efdfb1aa556487657ce06d2bc82ac0e
doc_id: 715375
cord_uid: 7xvqum64

There is limited evidence about the prognostic utility of right ventricular dysfunction (RVD) in patients with coronavirus disease 2019 (COVID‐19). We assessed the association between RVD and mortality in COVID‐19 patients. We searched electronic databases from inception to February 15, 2021. RVD was defined based on the following echocardiographic variables: tricuspid annular plane systolic excursion (TAPSE), tricuspid S′ peak systolic velocity, fractional area change (FAC), and right ventricular free wall longitudinal strain (RVFWLS). All meta‐analyses were performed using a random‐effects model. Nineteen cohort studies involving 2307 patients were included. The mean age ranged from 59 to 72 years and 65% of patients were male. TAPSE (mean difference [MD], −3.13 mm; 95% confidence interval [CI], −4.08–−2.19), tricuspid S′ peak systolic velocity (MD, −0.88 cm/s; 95% CI, −1.68 to −0.08), FAC (MD, −3.47%; 95% CI, −6.21 to −0.72), and RVFWLS (MD, −5.83%; 95% CI, −7.47–−4.20) were significantly lower in nonsurvivors compared to survivors. Each 1 mm decrease in TAPSE (adjusted hazard ratio [aHR], 1.22; 95% CI, 1.08–1.37), 1% decrease in FAC (aHR, 1.09; 95% CI, 1.04–1.14), and 1% increase in RVFWLS (aHR, 1.33; 95% CI, 1.19–1.48) were independently associated with higher mortality. RVD was significantly associated with higher mortality using unadjusted risk ratio (2.05; 95% CI, 1.27–3.31), unadjusted hazard ratio (3.37; 95% CI, 1.72–6.62), and adjusted hazard ratio (aHR, 2.75; 95% CI, 1.52–4.96). Our study shows that echocardiographic parameters of RVD were associated with an increased risk of mortality in COVID‐19 patients.

arrhythmias, and myocarditis/pericarditis. 2 The right ventricular compromise is increasingly recognized as an important complication in COVID-19 patients. 3 However, there is conflicted data about its prognostic utility in this population. Therefore, we performed a systematic review and meta-analysis to assess the association between right ventricular dysfunction (RVD) and mortality in COVID-19 patients.

This review was reported according to the preferred reporting items for systematic reviews and meta-analyses statement. 4 

We searched in the following databases: PubMed, Embase, Scopus, and Web of Science. The search was conducted from inception to February 15, 2021 . The complete search strategy is available in Table S1 . There were no restrictions on publication date or language.

Furthermore, we performed a manual search of reference lists of included studies and relevant reviews to identify additional studies.

The inclusion criteria were the following: (i) Cohort studies that included adult patients (≥18 years old) diagnosed with COVID-19 by reverse transcription-polymerase chain reaction and (ii) Studies that assessed the association between RVD assessed by echocardiography and mortality. We excluded commentaries, conference abstracts, systematic reviews, and narrative reviews.

We downloaded all articles from electronic search to EndNote X8 software and duplicate records were removed. Titles and abstracts were independently screened by two review authors (Carlos Diaz-Arocutipa and Jose Saucedo-Chinchay) to identify relevant articles.

Additionally, the same review authors (Carlos Diaz-Arocutipa and Jose Saucedo-Chinchay) independently examined the full-text of each article and registered reasons for the exclusion. Any disagreement on title/abstract and full-text selection was resolved by consensus.

We assess any of the following echocardiographic parameters: tricuspid annular plane systolic excursion (TAPSE), tricuspid S 0 peak systolic velocity, fractional area change (FAC), and right ventricular free wall longitudinal strain (RVFWLS). In addition, if available, the investigatordefined RVD was also evaluated.

The information from each study was independently extracted by two review authors (Carlos Diaz-Arocutipa and Jose Saucedo-Chinchay) using a standardized data extraction form that was previously piloted.

Any disagreement was resolved by consensus. We extracted the following data: first author name, year of publication, country, study design, sample size, population, age, sex, comorbidities, timing of echocardiographic evaluation, echocardiographic parameters of right ventricular function, and mortality.

The Newcastle-Ottawa scale (NOS) was used to assess the risk of bias of cohort studies. 5 Each study was classified into the following groups: low risk of bias (8-9 points), moderate risk of bias (5-7 points), and high risk of bias (0-4 points). The risk of bias was independently evaluated by two review authors (Carlos Diaz-Arocutipa and Jose Saucedo-Chinchay) and any disagreement was resolved by consensus.

We performed all meta-analyses using a random-effects model. The between-study variance was estimated using the Paule-Mandel estimator. 6 We pooled unadjusted and adjusted effect measures for binary variables and mean differences (MD) with their 95% confidence interval (95% CI) for continuous variables. In the case of studies that have only reported median and interquartile range, the mean and SD were estimated using the method published by Wan et al. 7 Heterogeneity among studies was evaluated using the chi-squared test (threshold p < .10) and I 2 statistic. Heterogeneity was defined as low if I 2 < 30%, moderate if I 2 = 30%-60%, and high if I 2 > 60%. Publications bias was assessed by visual inspection of funnel plots. Statistical tests for funnel plot asymmetry were not performed since at least 10 studies per outcome are required. Subgroup analyses were performed according to the type of population (consecutive vs. nonconsecutive) and proportion of mechanically ventilated patients (<50% vs. ≥50%). All meta-analyses were conducted using the meta package from R 3.6.3 (www.r-project.org). A two-tailed p < .05 was considered statistically significant.

Our electronic search retrieved 807 articles. After the removal of duplicates, 334 articles were screened by title/abstract, and of those, 253 were excluded. After a full-text assessment of 81 remaining articles, 62 were excluded due to no full-text (n=2), other population (n=5), conference abstract (n=5), commentary (n=8), other exposure (n=8), and other outcome (n=9). Finally, 19 articles were selected (Supplemental Figure 1 ). 8-26

The main characteristics of the included studies were summarized in Table 1 Table S2 . The echocardiographic parameters evaluated and the definitions of mortality and RVD can be found in Table S3 .

According to the NOS assessment, 10 studies had a moderate risk of bias and nine studies had a low risk of bias (Table S4) . None of the studies was scored as high risk of bias.

TAPSE was significantly lower (MD, À3.13 mm; 95% CI, À4.08 to À2.19; I 2 = 63%) in nonsurvivors compared to survivors ( Figure 1A ).

Each 1 mm decrease in TAPSE was significantly associated with a higher mortality using both unadjusted hazard ratio (uHR, 1.36; 95% CI, 1.15-1.62; I 2 = 94%) and adjusted hazard ratio (aHR, 1.22;

95% CI, 1.08-1.37; I 2 = 65%) (Figure 2A and Figure 3A ). Funnel plots did not show asymmetry ( Figure S2 ).

Tricuspid S 0 peak systolic velocity was significantly lower (MD, À0.88 cm/s; 95% CI, À1.68 to À0.08; I 2 = 0%) in nonsurvivors compared to survivors ( Figure 1B ). Funnel plot did not show asymmetry (- Figure S3 ). Each 1 cm/s decrease in tricuspid S 0 peak systolic velocity was significantly associated with higher mortality (uHR, 

FAC was significantly lower (MD, À3.47%; 95% CI, À6.21 to À0.72; I 2 = 72%) in nonsurvivors compared to survivors ( Figure 1C) . FAC was not significantly associated with higher mortality using an uHR (1.06; 95% CI, 0.99-1.13; I 2 = 82%) ( Figure 2C ). In contrast, the adjusted hazard ratio (aHR, 1.09; 95% CI, 1.04-1.14; I 2 = 0%) showed that each 1% decrease in FAC was significantly associated with higher mortality ( Figure 3B ). Funnel plots did not show asymmetry ( Figure S4 ).

RVFWLS was significantly lower (MD, À5.83%; 95% CI, À7.47 to À4.20; I 2 = 85%) in survivors compared to nonsurvivors ( Figure 1D ). RVFWLS was not significantly associated with higher mortality using aHR (1.18; 95% CI, 0.97-1.45; I 2 = 90%) ( Figure 2D ). In contrast, the adjusted hazard ratio (aHR, 1.33; 95% CI, 1.19-1.48; I 2 = 0%) showed that each 1% increase of RVFWLS was significantly associated with higher mortality ( Figure 3C ). Funnel plots did not show asymmetry ( Figure S5 ).

Overall, 22% of patients had RVD and the absolute risk of mortality in patients with RVD was 40% in eight studies. RVD was significantly associated with higher mortality using unadjusted risk ratio (uRR, 2.05; 95% CI, 1.27-3.31; I 2 = 64%), uHR (3.37; 95% CI, 1.72-6.62; I 2 = 46%), and adjusted hazard ratio (aHR, 2.75; 95% CI, 1.52-4.96; I 2 = 45%) ( Figure 4 ).

Funnel plots did not show asymmetry ( Figure S6 ). that ultimately results in RVD. We found that RVD was independently associated with an almost threefold increase in mortality in COVID-19 patients. Overall, our finding highlights the possible prognostic value of the right ventricular function assessment that can potentially improve the risk stratification of these patients.

remains incompletely understood. RVD may contribute to the rapid hemodynamic deterioration of these patients by affecting the left ventricular forward stroke volume. 31 Another possible explanation is that the presence of myocardial damage will provide the pathological substrate for malignant ventricular arrhythmias, predisposing to sudden cardiac death. However, although we found that RVD increases the risk of death in COVID-19 patients, it is also possible the option of a common cause for both problems.

In the context of COVID-19, the two main pathophysiological mechanisms that may explain RVD include increased afterload and impaired contractility. 32 Although both mechanisms can coexist, the first mechanism seems to predominate because the right ventricle is highly sensitive to changes in afterload.

There are some clinical conditions associated with SARS-CoV-2 infection that can lead to increased afterload such as pulmonary thromboembolism, acute respiratory distress syndrome, and mechanical ventilation in intubated patients. 32 Many studies have shown an elevated incidence of pulmonary thromboembolism in COVID-19

patients. 33 Acute respiratory distress syndrome is a major cause of death in COVID-19 patients with an incidence of up to 68% in hospitalized patients. 37 RVD is an independent predictor of mortality in ARDS patients and its development is attributed to the increased pulmonary vascular resistance, which is mediated by vascular remodeling, right ventricular-pulmonary arterial uncoupling, and thrombosis/vasoconstriction of the pulmonary vasculature. 38 Mechanical ventilation, especially when high levels of positive end-expiratory pressure are required, reduces venous return and increases pulmonary vascular resistance. 39 Considering that up to 33% of hospitalized patients with COVID-19 are mechanically ventilated, 40 the potential damage that this invasive therapy may cause to the right ventricle should be considered in all cases. Thus, the management of this equipment should be adequately optimized in order to reduce the risk of RVD.

Currently, it is recognized that several cardiac cells such as cardiomyocytes, pericytes, and fibroblasts can also express the ACE2 receptor and are therefore susceptible to infection by SARS-CoV-2. 36 Many cases of acute myocarditis in patients with COVID-19 have been described in the literature and it is considered a cause of right and/or left heart failure. 41 Interestingly, there are published autopsy reports that have shown lymphocytic infiltrates in the right ventricular myocardium of these patients. 35 Overall, it appears that direct viral damage, exacerbated systemic inflammatory response, and other pathogenic mechanisms such as epicardial and microvascular coronary artery disease secondary to thrombosis also contribute to the development of ventricular dysfunction in COVID-19 patients. 27 The assessment of right ventricular systolic function has historically been a difficult task given its complex geometric shape. Although echocardiography has some limitations, it remains the most commonly used imaging tool worldwide. 42 TAPSE, tricuspid S 0 peak systolic velocity, and FAC are the most frequently used echocardiographic parameters to evaluate right ventricular systolic function in daily clinical practice. 42, 43 Of note, these parameters can assess both longitudinal (e.g., TAPSE and tricuspid S 0 peak systolic velocity) and radial function (e.g., FAC) of the right ventricle. 44 More recent techniques such as speckle-tracking echocardiography are increasingly used to estimate the global and regional systolic function. 43 Therefore, the prevalence of RVD may be even higher in the COVID-19 setting. Finally, since most of the included studies did not report adjusted effects, there is an increased risk of bias in their pooled estimates. Although we also reported meta-analyses of adjusted estimates of available studies, there is still a possibility of residual confounding. Thus, our results should be interpreted with caution.

Our review shows that RVD was associated with an increased risk of mortality in COVID-19 patients. Among echocardiographic parameters, TAPSE, FAC, and RVFWLS were independently associated with higher mortality. Although our results need to be confirmed by prospective studies with larger sample sizes, they suggest that echocardiographic assessment of right ventricular systolic function may add prognostic information during the risk stratification of COVID-19

patients.

None of the authors reported any conflicts of interest. 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Carlos Diaz-Arocutipa https://orcid.org/0000-0002-5101-2832

Jose Saucedo-Chinchay https://orcid.org/0000-0003-4938-2241

Edgar Argulian https://orcid.org/0000-0003-2106-2668

WHO Coronavirus Disease (COVID-19) Dashboard

COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives

Right ventricular damage in COVID-19: association between myocardial injury and COVID-19

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis

Comparative performance of heterogeneity variance estimators in meta-analysis: a review of simulation studies

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Advanced echocardiographic phenotyping of critically ill patients with coronavirus-19 sepsis: a prospective cohort study

Prognostic utility of quantitative offline 2D-echocardiography in hospitalized patients with COVID-19 disease

Reduced cardiac function is associated with cardiac injury and mortality risk in hospitalized COVID-19 patients

Prospective multicentre cohort study of transthoracic echocardiography provision in the south west of the UKduring the first wave of SARS-CoV-2 pandemic

Right ventricular-arterial uncoupling independently predicts survival in COVID-19 ARDS

Right ventricular function and pulmonary pressures as independent predictors of survival in patients with COVID-19 pneumonia

D-dimer and right ventricular abnormalities as prognostic factors in critically ill COVID-19 patients

Prognostic utility of right ventricular remodeling over conventional risk stratification in patients with COVID-19

Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 study

The prevalence, risk factors and outcome of cardiac dysfunction in hospitalized patients with COVID-19

Prognostic value of right ventricular longitudinal strain in patients with COVID-19

Echocardiographic findings in patients with COVID-19 pneumonia

Impact of right ventricular dysfunction on mortality in patients hospitalized with COVID-19

Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19

Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection

The predictive role of left and right ventricular speckle-tracking echocardiography in COVID-19

A pilot study on right ventricular longitudinal strain as a predictor of outcome in COVID-19 patients with evidence of cardiac involvement. Echocardiography

The predictive role of combined cardiac and lung ultrasound in Coronavirus Disease

Biventricular longitudinal strain predict mortality in COVID-19 patients

Left and right ventricular dysfunction in patients with COVID-19-associated myocardial injury

Prognostic value of right ventricular dilatation in patients with COVID-19: a multicentre study

Clinical conditions and echocardiographic parameters associated with mortality in COVID-19

Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study

Anatomy, function, and dysfunction of the right ventricle: JACC state-ofthe-art review

In the eye of the storm: the right ventricle in COVID-19

Elsayed NMathlouthi AMarmor RClary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis

Characteristics of coagulation alteration in patients with COVID-19

Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study

The right ventricle in COVID-19

Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey

The right ventricle in ARDS

Physiologic approach to mechanical ventilation in right ventricular failure

Mechanical ventilation in COVID-19: interpreting the current epidemiology

COVID-19 and myocarditis: a systematic review and overview of current challenges

Echocardiographic assessment of right ventricular function: current clinical practice

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Echocardiographic assessment of the right heart in adults: a practical guideline from the British Society of Echocardiography

Association between right ventricular dysfunction and mortality in COVID-19 patients: A systematic review and meta-analysis